Immunotherapy for gynaecological malignancies
G Coukos, JR Conejo-Garcia… - Expert opinion on …, 2005 - Taylor & Francis
Expert opinion on biological therapy, 2005•Taylor & Francis
Gynaecological malignancies, excluding breast cancer, cause~ 25,000 deaths yearly
among women in the US. Therefore, novel approaches for the prevention or treatment of
these diseases are urgently required. In the case of cervical cancer, human papillomavirus
(HPV) xenoantigens are readily recognised by the immune system, and their targeting has
shown great promise in preclinical models of therapeutic vaccination and in clinical studies
of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also …
among women in the US. Therefore, novel approaches for the prevention or treatment of
these diseases are urgently required. In the case of cervical cancer, human papillomavirus
(HPV) xenoantigens are readily recognised by the immune system, and their targeting has
shown great promise in preclinical models of therapeutic vaccination and in clinical studies
of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also …
Gynaecological malignancies, excluding breast cancer, cause ~ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.
Taylor & Francis Online